What DIM dose do labels and studies give for men?
| Source | Strength or daily amount | Schedule |
|---|---|---|
| US capsule label (TEMPO BALANCE, a combination product labelled for healthy hormone balance for women) | 150 mg DIM per capsule5 | 1 capsule daily, preferably with a meal or as directed by a healthcare professional5 |
| Health Canada monograph | 60 to 200 mg DIM per day for adults 18 and over (estrogen metabolism and breast pain claims); not more than 200 mg a day (antioxidant claim)1 | Daily quantity; no directions required1 |
| Reed 2008 single-dose trial (not a label; 6 groups of 4 healthy men and women aged 22 to 58) | 50 mg DIM per capsule supplied6 | Single doses of 50, 100, 150, 200 and 300 mg, with the 300 mg dose repeated in an additional group and 1 of each 4 on placebo6 |
Health Canada's monograph gives 60 to 200 mg of DIM a day for adults 18 and over under its healthy estrogen metabolism and recurrent breast pain claims,1 and trials in men with prostate cancer or prostatic intraepithelial neoplasia gave 100 or 200 mg twice daily or placebo for 21-28 days in 45 men,2 225 mg twice daily for 14-72 days in 41 men with no placebo arm3 and 900 mg a day or placebo for 3 months in 14 men.4
DIM strengths and schedules as labelled
The table is set at the top of the page
The one US label found, TEMPO BALANCE on DailyMed, is a combination capsule labelled for healthy hormone balance for women, with black pepper fruit extract, broccoli extract and calcium D-glucarate, 30 capsules per container.5 Other strengths are not sourced.
DIM doses used in trials in men
No trial in healthy men alone or in men on testosterone turned up: the trials in men below enrolled men with prostate cancer or prostatic intraepithelial neoplasia, and the healthy-volunteer trials, such as the Reed single-dose trial above, mixed men and women.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Gee 2016 phase Ib prostatectomy trial | 100 or 200 mg absorption-enhanced DIM twice daily, or placebo2 | 45 men with organ-confined prostate cancer scheduled for radical prostatectomy2 | 21-28 days2 |
| Heath phase II B-DIM trial (NCT00888654, results submitted 2015) | 225 mg B-DIM orally twice daily, single arm with no placebo3 | 41 men with prostate cancer undergoing prostatectomy3 | 14-72 days3 |
| Heath phase I trial (NCT00305747, registered 2006) | Started at 75 mg BR-DIM twice daily, escalated in cohorts of 3-6 patients7 | 12 men with nonmetastatic, hormone-refractory prostate cancer7 | 28-day courses, up to 127 |
| Paltsev 2014 Infemin phase Ib trial | 900 mg DIM a day (three 150 mg capsules twice a day), or placebo4 | Fourteen men aged 18 to 60 with prostatic intraepithelial neoplasia4 | 3 months (interim; trial planned for 12 months)4 |
When and how DIM is taken
Beside the US label's 1 capsule daily, preferably with a meal or as directed by a healthcare professional,5 the NCT00305747 entry had patients take tablets twice daily with or without food,7 and the Reed single-dose trial gave its dose after an overnight fast.6 No label gives a step schedule.
Side effects and cautions reported for DIM
In the Reed single-dose trial in 6 groups of 4 healthy men and women, no DIM-related adverse effects were reported up to 200 mg, though one subject at 150 mg and one at 200 mg complained of flatulence, and all adverse events were classified as grade I, defined as mild.6 At 300 mg, one of six people reported mild nausea and headache and one also reported vomiting; only the vomiting was judged as probably related to DIM, and one person on placebo reported nausea and headache.6 In interim results, the Paltsev Infemin trial reported three mild adverse events, nausea and diarrhea, in 2 of its 14 men (14%), a count that covers both the Infemin and placebo arms, and no serious adverse events over 3 months.4 The NCT00888654 registry entry lists headache as a serious adverse event in 2 of 41 men taking 225 mg B-DIM twice daily.3 Health Canada's monograph lists a contraindication for all products: do not use if pregnant or breastfeeding.1 For products providing 6 mg or more of DIM a day, Health Canada's monograph says to ask a health care practitioner before use when taking medications or natural health products or attempting to conceive, and, for the male subpopulation only, when there is a liver disorder or symptoms of low estrogen such as joint pain, mood changes or changes in libido.1 The US label tells pregnant or nursing mothers, children under 18 and people with a known medical condition to consult a physician.5 The same caution line on the US label begins with a warning not to exceed the dose of one capsule daily.5
Storing DIM capsules
The US label's storage line is a cool, dry place, with no temperature or time stated.5 Health Canada's monograph gives no figure either.1 Neither source gives stability data.
Frequently asked questions
References
- Health Canada. [TEMPLATE FOR SHORT FORM MONOGRAPHS (Jan 1st 2004)]. webprod.hc-sc.gc.ca
- PubMed. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. 2016. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00888654: Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy. 2015. clinicaltrials.gov
- EPMA J. Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN). 2014. pmc.ncbi.nlm.nih.gov
- DailyMed (Pronova Corporation). TE MPO TM BALANCE. 2023. dailymed.nlm.nih.gov
- Cancer Epidemiol Biomarkers Prev. Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3, 3′-Diindolylmethane in Healthy Subjects. 2008. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00305747: Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy. 2010. clinicaltrials.gov